Latigo Biotherapeutics Secures $150M for Non-Opioid Pain Solutions

Latigo Biotherapeutics has successfully closed a $150 million Series B financing round, primarily aimed at advancing its non-opioid pain treatments, particularly its lead candidate LTG-001, a selective Nav1.8 inhibitor for acute pain relief. The financing was led by Blue Owl Capital, with participation from various investors including Sanofi Ventures and Qatar Investment Authority. Latigo's CEO, Nima Farzan, emphasized the urgent need for non-opioid alternatives in pain management, especially in light of the ongoing opioid crisis. The company has reported positive Phase 1 trial results for LTG-001, indicating its potential as a well-tolerated and rapidly absorbed treatment. Additionally, Latigo is progressing with LTG-305, another Nav1.8 inhibitor currently in Phase 1 trials for chronic pain. As the market for pain relief continues to evolve, Latigo aims to establish itself as a key player with innovative, non-addictive solutions.